Subscribe to NRx Newsletter

Home

Hope • Science • Life

Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx Pharmaceuticals, was interviewed again for a broadcast hosted by AdvisorShares.

Interview discusses NRX's latest FDA milestone for its preservative-free ketamine product KETAFREE™, what it means for patients and investors, and how novel therapeutics are shaping the future of medicine.

Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx Pharmaceuticals, was interviewed again for a broadcast hosted by AdvisorShares.

Interview discusses NRX's latest FDA milestone for its preservative-free ketamine product KETAFREE™, what it means for patients and investors, and how novel therapeutics are shaping the future of medicine.

Hope for people with life-threatening depression and PTSD

NRx is developing breakthrough medicines for people with life-threatening depression and PTSD. Our lead candidate, NRX-101, is the first oral medication in FDA trials for suicidal bipolar depression.

Hope for people with life-threatening depression and PTSD

NRx is developing breakthrough medicines for people with life-threatening depression and PTSD. Our lead candidate, NRX-101, is the first oral medication in FDA trials for suicidal bipolar depression.

HOPE Therapeutics Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics

HOPE Therapeutics Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics

Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, presents at Noble Capital Markets Virtual Emerging Growth Conference

Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, presents at Noble Capital Markets Virtual Emerging Growth Conference

Every 27 seconds someone in the U.S. attempts suicide

11-20% of people with bipolar disorder will die by suicide

0 Approved drugs exist today for suicidal bipolar depression

NRx-101 is the first investigational drug in FDA trials for suicidal bipolar depression, awarded fast track designation, breakthrough therapy designation, and a special protocol agreement by the FDA. Positive Phase 2 data*.

Latest News View all >

As many as 50% of individuals with bipolar disorder attempt suicide or have serious thoughts of suicide and between 11-20% of those attempt and succumb to suicide.





Source:
Pallaskorpi, et al. “Incidence and predictors of suicide attempts in bipolar I and II disorders: A 5-year follow-up study,” Bipolar Disorders, 2016
“Suicide Attempts and Completions in Patients With Bipolar Disorder,” Psychiatric Times, 2007

NRX-101 is an investigational treatment for bipolar depression in patients with Acute and Sub-Acute Suicidal Ideation and Behavior (ASIB, SSIB)

Our Science: Targeting The NMDA Receptor

The brain’s NMDA receptor is a newly validated target for treating suicidal ideation and depressive symptoms.

Our Pipeline

We are investigating our non-hallucinogenic, non-addictive, non-neurotoxic approach to NDMA inhibition for suicidal bipolar depression and PTSD.

Resources & Patient Stories

We’re bringing hope to life for people with severe bipolar depression and PTSD, and we are currently investigating our approach in ongoing clinical trials.

Our Company

NRx is a clinical biopharma company focused on the high unmet need for lifesaving treatments for people with severe bipolar depression and PTSD in the presence of suicidality.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

Read More